Fulcrum Therapeutics, Inc.
3.84USD
+0.0200 (+0.52%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | — | 0 | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -29 | -22 | -23 | -22 | -20 | -20 | -19 | -25 |
| Net Income | -26 | -19 | -20 | -20 | -17 | -18 | -17 | -22 |
| EPS (Diluted) | $-0.34 | $-0.25 | $-0.31 | $-0.31 | $-0.28 | $-0.28 | $-0.27 | $-0.35 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)